Key result
Idarubicin monotherapy achieved complete and partial remissions in 49% of children with prognostically poor recurrences of acute lymphoblastic leukemia.
Why the study?
Does idarubicin monotherapy induce remission in children with recurrent acute lymphoblastic leukemia?
Population
51 children with prognostically poor recurrences of acute lymphoblastic leukemia, all previously exposed to…
Design
Cohort
Follow-up
2 weeks
Authors
Loading...
May offer remission option in poor-prognosis relapsed pediatric ALL; leaves open randomized confirmation of net benefit.
Does idarubicin monotherapy induce remission in children with recurrent acute lymphoblastic leukemia?
Idarubicin monotherapy is effective for remission induction in children with recurrent ALL, though acute hematological toxicity is dose-limiting.
Neuendank et al. (1997) studied Childhood acute lymphoblastic leukemia (n=51). Idarubicin was evaluated on Complete and partial remissions (reduction of leukemic blasts in the bone marrow and other compartments 2 weeks later). Idarubicin monotherapy achieved complete and partial remissions in 49% of children with prognostically poor recurrences of acute lymphoblastic leukemia.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: